Great potential seen for Eli Lilly's Mounjaro in obesity and type 2 diabetes

15 June 2023

The recent rally in Eli Lilly’s (NYSE: LLY) market value, which made it to become the most valuable pharmaceutical company in the world, with a market cap of $420 billion, surpassing Johnson & Johnson (NYSE: JNJ), has come as the result of its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completing its second final-stage trial for obesity.

Due to significant weight loss induced by it, Mounjaro is likely to become the leading therapy in obesity and T2D, says data and analytics company GlobalData.

There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5% of patients’ body weight (52lbs or 24kg) and greater than 50% of patients taking Mounjaro achieving at least 20% body weight reductions. As a result of Mounjaro, Lilly will remain as one of the most highly valued pharmaceutical companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK